BMS Report Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable Non-Small Cell Lung Cancer

October 8, 2020 Auto Bot BMS, Clinical Trials, CT, Nivolumab, Opdivo, P-III, Report, results, Trial 0

Shots:

  • The P-III CheckMate-816 study involves assessing of Opdivo (360mg) + CT (q3w for 3 doses) vs CT (q3w for 3 doses), followed by surgery as a neoadjuvant treatment in 358 patients with resectable NSCLC
  • The study met its 1EPs of improved pathologic complete response. The positive results marks the first time an immune checkpoint inhibitor-based combination has demonstrated superior efficacy as neoadjuvant therapy in a P-III trial in resectable NSCLC
  • The study is ongoing to assess other 1EPsof EFS. Opdivo-based treatments demonstrated benefit in 4 P-III clinical trials in early-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma

Click here ­to­ read full press release/ article | Ref: BMS | Image: BMS

The post BMS Report Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable Non-Small Cell Lung Cancer first appeared on PharmaShots.